Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, for what reasons epilepsy is allocated only one achievement point in the General Medical Services Statement of Financial Entitlements (Amendment) Directions 2019; and what steps he is taking to ensure that GP's put women who are prescribed Valproate and able to have children on a pregnancy prevention programme.

Epilepsy is allocated one achievement point within the Quality and Outcomes Framework (QOF) in the General Medical Services Statement of Financial Entitlements (Amendment) (No.2) Directions 2022. QOF clinical indicators are subject to approval by the National Institute for Health and Care Excellence (NICE) and are underpinned by NICE clinical guidelines and are subject to consultation with the General Practitioners Committee of the British Medical Association.

Sodium valproate must not be used in any woman or girl able to have children unless she has a Pregnancy Prevention Programme in place. This is laid out in guidance issued by the Medicines and Healthcare products Regulatory Agency, last updated in February 2021, which can be found at the following link:

https://www.gov.uk/guidance/valproate-use-by-women-and-girls.

The programme is designed to make sure patients are fully aware of the risks and the need to avoid becoming pregnant. It includes the completion of a signed risk acknowledgement form when their treatment is reviewed by a specialist, which must take place at least annually.

A Valproate Registry has been set up which, in line with a recommendation of the Cumberlege review, has been extended to other antiepileptic drugs taken during pregnancy. It includes all women in England who are taking National Health Service (NHS) prescribed valproate and identifies when they are pregnant and accessing NHS care for that pregnancy. The registry improves our ability to monitor implementation and compliance with the Pregnancy Prevention Programme.